Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples